<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02517463</url>
  </required_header>
  <id_info>
    <org_study_id>UW10-392</org_study_id>
    <nct_id>NCT02517463</nct_id>
  </id_info>
  <brief_title>Ulipristal Emergency Contraception Used Before or After Ovulation</brief_title>
  <official_title>Observational Study on the Clinical Efficacy of Ulipristal for Emergency Contraception When Administered Before or After Ovulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Family Planning Association of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a prospective, open-label, single-drug, uncontrolled, observational clinical study.

      Women attending the Family Planning Association of Hong Kong (FPAHK) for emergency
      contraception within 120 hours of UPSI were recruited. Subjects were recruited from both the
      Birth Control Clinics and Youth Health Care Centres of the FPAHK.

      Depending on the timing in relation to ovulation in the current menstrual cycle at the time
      of presentation, the women were classified into two groups:

      Group 1: pre-ovulatory Group 2: post-ovulatory

      After counseling and obtaining informed consent, eligible subjects received a single dose of
      ulipristal acetate 30 mg (ellaOne®) under direct supervision. A baseline blood test for
      hormonal profile (LH, oestradiol and progesterone) and ultrasound scan for ovarian follicle
      assessment were carried out by a designated doctor or research nurse at the clinic visit.

      The subjects were advised not to have further acts of coitus before the return of
      menstruation. They were given a diary chart to record vaginal spotting and bleeding, possible
      side effects and further acts of intercourse, if any, and the contraceptive method used. A
      follow-up appointment were be arranged about 1-2 weeks after the expected next menstruation.
      Any events of unplanned pregnancy and adverse effects were recorded for analysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Pregnancies Prevented (PPP)</measure>
    <time_frame>one cycle (i.e. up to about 4 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure Rate</measure>
    <time_frame>one cycle (i.e. up to about 4 weeks)</time_frame>
    <description>Number of subjects who got pregnant / Total number of subjects in the group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Length of the Index Menstrual Cycle From Baseline</measure>
    <time_frame>one cycle (i.e. up to about 4 weeks)</time_frame>
    <description>shortening or lengthening of the index menstrual cycle compared to the previous menstrual pattern of the subject</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">700</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Pre-ovulatory</arm_group_label>
    <description>Ulipristal acetate 30 mg single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-ovulatory</arm_group_label>
    <description>Ulipristal acetate 30 mg single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulipristal acetate</intervention_name>
    <description>This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.</description>
    <arm_group_label>Post-ovulatory</arm_group_label>
    <arm_group_label>Pre-ovulatory</arm_group_label>
    <other_name>Ella</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 700 women attending the Family Planning Association of Hong Kong for emergency
        contraception who fulfilled the inclusion criteria and not meeting the exclusion criteria
        were recruited.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy women aged 18 years or above;

          2. Regular menstrual cycles (every 21-35 days) within the past three cycles;

          3. Requesting emergency contraception within 120 h of a single act of unprotected
             intercourse in the current menstrual cycle;

          4. Willing to abstain from further acts of unprotected intercourse and;

          5. Available for follow-up over the next 6 weeks

        Exclusion Criteria:

          1. Post-abortion or postpartum patients whose period had not yet returned

          2. Regular use of prescription drugs before admission to the study and

          3. Intercourse during the treatment cycle more than 120 h before admission into the
             study.

          4. Found pregnant at the time of presentation

          5. Breastfeeding women

          6. Women who have been sterilized (or partner being sterilized) or have intrauterine
             contraceptive device in-situ

          7. Uncertain about the date of the last menstrual period

          8. Women who had used hormonal contraceptive in the current or past one cycle
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hang Wun Raymond Li, MBBS, FRCOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>August 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2015</study_first_posted>
  <results_first_submitted>September 13, 2015</results_first_submitted>
  <results_first_submitted_qc>October 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2018</results_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Hang Wun Raymond Li</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Emergency contraception</keyword>
  <keyword>ulipristal acetate</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulipristal acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>700 women were recruited at a community family planning clinic of the Family Plannng Association of Hong Kong, Hong Kong, between May 2011 and March 2014</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pre-ovulatory</title>
          <description>Ulipristal acetate 30 mg single oral dose
Ulipristal acetate: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.</description>
        </group>
        <group group_id="P2">
          <title>Post-ovulatory</title>
          <description>Ulipristal acetate 30 mg single oral dose
Ulipristal acetate: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="369"/>
                <participants group_id="P2" count="331"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="364"/>
                <participants group_id="P2" count="329"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pre-ovulatory</title>
          <description>Ulipristal acetate 30 mg single oral dose
Ulipristal acetate: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.</description>
        </group>
        <group group_id="B2">
          <title>Post-ovulatory</title>
          <description>Ulipristal acetate 30 mg single oral dose
Ulipristal acetate: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="364"/>
            <count group_id="B2" value="329"/>
            <count group_id="B3" value="693"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="364"/>
                    <measurement group_id="B2" value="329"/>
                    <measurement group_id="B3" value="693"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" lower_limit="28" upper_limit="37"/>
                    <measurement group_id="B2" value="34" lower_limit="28" upper_limit="39"/>
                    <measurement group_id="B3" value="32" lower_limit="28" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="364"/>
                    <measurement group_id="B2" value="329"/>
                    <measurement group_id="B3" value="693"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="355"/>
                    <measurement group_id="B2" value="322"/>
                    <measurement group_id="B3" value="677"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="364"/>
                    <measurement group_id="B2" value="329"/>
                    <measurement group_id="B3" value="693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Pregnancies Prevented (PPP)</title>
        <time_frame>one cycle (i.e. up to about 4 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-ovulatory</title>
            <description>Ulipristal acetate 30 mg single oral dose
Ulipristal acetate: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Post-ovulatory</title>
            <description>Ulipristal acetate 30 mg single oral dose
Ulipristal acetate: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Pregnancies Prevented (PPP)</title>
          <units>percentage of pregnancies prevented</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="364"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5"/>
                    <measurement group_id="O2" value="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The PPP from a previous study was 67.2%. Assuming the PPP in the “preovulatory” and “post-ovulatory” groups were equivalent, and taking 10% to be the maximum permitted difference for equivalence, a minimum of 273 subjects in each group would be required to confirm equivalence between the two groups with a power of 80% and type I error of 0.05. Therefore, our recruitment of 700 subjects with more than 300 in each group was sufficient.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Failure Rate</title>
        <description>Number of subjects who got pregnant / Total number of subjects in the group</description>
        <time_frame>one cycle (i.e. up to about 4 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-ovulatory</title>
            <description>Ulipristal acetate 30 mg single oral dose
Ulipristal acetate: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Post-ovulatory</title>
            <description>Ulipristal acetate 30 mg single oral dose
Ulipristal acetate: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Failure Rate</title>
          <description>Number of subjects who got pregnant / Total number of subjects in the group</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="364"/>
                <count group_id="O2" value="329"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.564</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Length of the Index Menstrual Cycle From Baseline</title>
        <description>shortening or lengthening of the index menstrual cycle compared to the previous menstrual pattern of the subject</description>
        <time_frame>one cycle (i.e. up to about 4 weeks)</time_frame>
        <population>Only subjects with follow-up information were included in this part of analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-ovulatory</title>
            <description>Ulipristal acetate 30 mg single oral dose
Ulipristal acetate: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.</description>
          </group>
          <group group_id="O2">
            <title>Post-ovulatory</title>
            <description>Ulipristal acetate 30 mg single oral dose
Ulipristal acetate: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Length of the Index Menstrual Cycle From Baseline</title>
          <description>shortening or lengthening of the index menstrual cycle compared to the previous menstrual pattern of the subject</description>
          <population>Only subjects with follow-up information were included in this part of analysis</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="322"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="-1" lower_limit="-3" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pre-ovulatory</title>
          <description>Ulipristal acetate 30 mg single oral dose
Ulipristal acetate: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.</description>
        </group>
        <group group_id="E2">
          <title>Post-ovulatory</title>
          <description>Ulipristal acetate 30 mg single oral dose
Ulipristal acetate: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Minor complaints</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="364"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Raymond Li</name_or_title>
      <organization>The University of Hong Kong</organization>
      <phone>+852 22553914</phone>
      <email>raymondli@hku.hk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

